08/18/2025
3:05 PM | Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
IAF, LLC (Filed by)
| Form SCHEDULE 13G/A | |
07/07/2025
7:00 PM | Ernexa Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Gurrola Sandra M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/19/2025
11:15 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form EFFECT | |
06/11/2025
7:34 PM | Cherington Charles (Reporting)
Ernexa Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2025
7:39 PM | Cherington Charles (Filed by)
Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
| Form SCHEDULE 13D/A | |
06/11/2025
3:30 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
06/11/2025
3:35 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/15/2025
8:13 PM | Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
HALPERN JOHN D (Filed by)
| Form SCHEDULE 13G/A | |
05/15/2025
3:42 PM | Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
Konar Shameek (Filed by)
| Form SCHEDULE 13G | |
05/14/2025
7:39 PM | Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
IAF, LLC (Filed by)
| Form SCHEDULE 13G/A | |
05/14/2025
1:14 PM | Ernexa Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
Freebird Partners LP (Filed by)
| Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for ERNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
05/07/2025
10:48 AM | Cherington Charles (Reporting)
Ernexa Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4/A | |
04/29/2025
11:15 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form EFFECT | |
04/16/2025
3:30 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/14/2025
4:05 PM | Ernexa Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form ARS | |
04/04/2025
9:54 AM | Cherington Charles (Reporting)
Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/04/2025
9:55 AM | Cherington Charles (Filed by)
Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
| Form SCHEDULE 13D/A | |
04/03/2025
4:17 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form PRE 14A | |
04/03/2025
7:55 AM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/26/2025
6:30 AM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/24/2025
3:30 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/12/2025
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/12/2025
3:20 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/05/2025
4:55 PM | Cherington Charles (Filed by)
Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
| Form SCHEDULE 13D/A | |
02/14/2025
8:30 PM | Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
Singer Nicholas Jason (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
7:36 PM | Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
HALPERN JOHN D (Filed by)
| Form SCHEDULE 13G/A | |
02/12/2025
4:54 PM | Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
IAF, LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
6:00 PM | Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Luther Sanjeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/10/2025
6:00 PM | Cicala Peter (Reporting)
Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/10/2025
6:00 PM | Bristol James Arthur (Reporting)
Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/10/2025
6:00 PM | Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Gurrola Sandra M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/10/2025
6:00 PM | Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Wexler William A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/28/2025
4:31 PM | Eterna Therapeutics Inc. (Subject)
Ernexa Therapeutics (Subject)
Freebird Partners LP (Filed by)
| Form SCHEDULE 13G/A | |
01/14/2025
4:00 PM | Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Ratner Elena (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/14/2025
4:01 PM | Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
Ratner Elena (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/18/2024
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 424B3 | |
11/18/2024
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 424B3 | |
11/18/2024
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 424B3 | |
11/17/2024
11:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form EFFECT | |
11/14/2024
5:45 AM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
11/14/2024
5:45 AM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
Why More Investors Are Using Family Trusts to Protect Their Wealth (Ad) For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026.
If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest. Click here to get your free advisor matches and start planning your legacy today. |
11/05/2024
3:30 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
11/05/2024
11:42 AM | Cherington Charles (Reporting)
Eterna Therapeutics Inc. (Issuer)
Ernexa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/29/2024
3:30 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/16/2024
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form ARS | |
09/27/2024
3:47 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form PRE 14A | |
09/27/2024
3:15 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/25/2024
3:36 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
3:30 PM | Eterna Therapeutics Inc. (Filer)
Ernexa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
MarketBeat All Access